Elmiron vision loss lawsuit MDL 2973: pigmentary maculopathy, the 1996-to-2020 warning lag, and the ongoing confidential Janssen settlements

If you took Elmiron for interstitial cystitis (IC) and have developed unexplained vision problems, this is the litigation that may concern you. Elmiron, the brand name for pentosan polysulfate sodium (PPS), is the only FDA-approved oral medication for interstitial cystitis. Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) has marketed it since 1996. The drug works (the mechanism is poorly understood but it provides relief for many IC patients who have few other options), but in 2018, researchers at Emory Eye Center published the first studies linking long-term Elmiron use to a previously unrecognized form of retinal damage. They called it pigmentary maculopathy. It is unique to Elmiron users. There is no cure.

The MDL is In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, MDL 2973, pending in the U.S. District Court for the District of New Jersey before Judge Brian Martinotti. As of March 2026, 634 cases are pending. That number is down sharply from the peak of 1,911 in early 2024, but the decline reflects confidential settlements that Janssen has been entering since 2023 rather than dismissals on the merits.

The science

Pigmentary maculopathy is a degenerative retinal condition that appears in the macula, which is the central area of the retina responsible for sharp central vision. It causes progressive central vision damage. The earliest symptoms patients report are difficulty reading, problems adapting to low light, and blurred or distorted vision. Late-stage progression includes substantial vision loss.

The condition is unique to Elmiron. It does not appear in patients with similar medical histories who have not taken the drug. The 2018 Emory study by Pearce and colleagues identified six patients with characteristic retinal findings, all of whom had taken Elmiron for an average of 15 years. Subsequent studies from Kaiser Permanente, the American Academy of Ophthalmology, and others confirmed the link and quantified the risk. Kaiser Permanente's 2019 study found toxicity rates as high as 42% at high cumulative doses, defined as 1,500 grams or more of total exposure (about five years at the standard 300 mg/day dose).

The dose-response relationship is what matters for individual cases. Patients with higher cumulative doses have higher risk. Patients with longer exposure periods have higher risk. There is some evidence that risk continues to develop even after discontinuation, which means a patient who stopped Elmiron in 2019 may develop pigmentary maculopathy in 2026 and the case is still actionable.

The condition is irreversible. Once retinal pigment damage occurs, the existing damage does not reverse. Some patients stabilize after discontinuation; some continue to deteriorate. There is no treatment that restores the lost retinal function.

The warning lag

The litigation theory turns on the gap between when Janssen knew or should have known about the vision risk and when the warning label changed.

Elmiron was approved by FDA in 1996. Janssen's adverse event database included reports of retinal pigmentary changes in Elmiron users from at least the early 2000s. The 2018 Emory study made the link public. In June 2020, FDA updated the Elmiron label to include a warning for "changes in the retina of the eye (pigmentary maculopathy)." That is 24 years after approval and approximately 18 years after Janssen would have had internal adverse event data suggesting the connection.

The plaintiffs' core argument is that Janssen had a duty to warn about pigmentary maculopathy risk substantially before 2020, that the warning could and should have been added years earlier as adverse event data accumulated, and that the delay caused patients to take cumulative doses they would not have taken if they had been informed of the risk. The case is a failure-to-warn product liability case rather than a defective-design case; the drug works for its intended purpose, but the warning was inadequate.

Janssen contests every link in this chain: that the early adverse event data was sufficient to require a warning, that the science before 2018 was clear enough to support causation, and that individual plaintiffs would have made different treatment decisions with better information.

The bellwether trial that didn't happen

The first bellwether trial in MDL 2973 was Maria Windham v. Janssen Pharmaceuticals (Case No. 20-cv-14670). It was originally scheduled for January 2023. Then March 2023. Then postponed again. The repeated delays are unusual in a mass tort of this size, and they reflect both the complexity of the medical causation evidence and Janssen's strategic preference for confidential individual resolution over public verdicts.

A second bellwether was scheduled for March 2023 and a third for May 2023. None has gone to trial as of early 2026. The Plaintiffs' Steering Committee (14 attorneys approved by Judge Martinotti to coordinate the litigation) has continued to develop the case file, and the parties have continued to settle individually.

The strategic implication: there is no public benchmark for Elmiron settlement values, because no jury has rendered a verdict. Confidential settlements have been negotiated since 2023, and the case decline from 1,911 to 634 in roughly 18 months suggests substantial resolution activity, but the per-case values are not part of the public record. Counsel handling Elmiron cases assess values based on injury severity, cumulative dose documentation, and the timing of diagnosis relative to discontinuation.

What documentation matters

Two pieces of evidence carry most of the weight.

Cumulative dose documentation is the foundation. Elmiron is typically prescribed at 300 mg per day, three times daily as needed. Pharmacy records establish the prescription history (dates of fill, quantities, refills). Cumulative grams of exposure is calculated from those records. Higher cumulative dose generally produces stronger cases; patients with 1,500+ grams of exposure are in the high-risk category for both the medical condition and the settlement valuation.

Diagnostic documentation of pigmentary maculopathy is the second pillar. Ophthalmologist examination findings, optical coherence tomography (OCT) imaging, fundus autofluorescence imaging, and the differential diagnosis ruling out other causes of macular degeneration all matter. The condition has characteristic findings on OCT and autofluorescence that distinguish it from age-related macular degeneration; the diagnostic documentation has to demonstrate those findings.

Treating ophthalmologist statements connecting the maculopathy to Elmiron exposure are useful but not strictly necessary; the medical literature has been clear since 2019 that this is a recognized pharmaceutical injury.

The interstitial cystitis question

A few patients have asked whether continuing Elmiron treatment affects their case. The answer is: it does not preclude filing, but cumulative dose matters. Patients who stopped Elmiron after the 2020 warning generally have stronger cases than patients who continued for years afterward, because the post-warning exposure is harder to attribute to failure-to-warn theories.

For IC patients still on Elmiron in 2026, the medical question is independent of the legal question. The drug remains FDA-approved with the warning now on the label. Treatment decisions are between you and your physician. If you have alternatives that have not been tried, the warning label is the prompt to evaluate them. The American Urological Association IC guidelines discuss second-line and third-line treatment options.

Statute of limitations

Most states give two to four years from the date the patient knew or reasonably should have known their vision injury was caused by Elmiron. The discovery rule applies in most jurisdictions; the FDA warning label change in June 2020 is often treated as the constructive notice point. Patients diagnosed with pigmentary maculopathy in 2020-2023 generally remain within the limitations period as of early 2026 in most states, but several states (Tennessee, Louisiana) have shorter periods, and individual analysis is required.

If your symptoms developed before 2020 but you were not formally diagnosed with pigmentary maculopathy until later (because the diagnosis didn't exist as a recognized condition until 2018, and many ophthalmologists weren't screening for it until after the FDA label change), the discovery rule generally protects the case.

How Elmiron fits in the broader pharmaceutical mass tort landscape

The fact pattern shares features with several other Halstonberg-covered litigations. Tepezza hearing loss involves a warning gap on a serious adverse event. Singulair montelukast involves long-term cumulative exposure to a widely-prescribed drug with delayed warning recognition. Suboxone tooth decay involves irreversible injury from chronic use of an approved medication. Each of those litigations has produced different procedural and settlement outcomes; Elmiron is on the slower-moving end because Janssen has chosen confidential resolution over bellwether trials.

For the ongoing personal injury and economic loss settlements in the related Valsartan NDMA framework, the procedural model is closer to traditional MDL bellwether progression. Elmiron has stayed mostly out of the public docket.

Practical next steps

If you took Elmiron for an extended period and have any visual symptoms (difficulty reading, problems with low light, blurred central vision, distorted shapes), see a retinal specialist for diagnostic evaluation. The conditions checked for are pigmentary maculopathy and any related retinal pigment epithelium changes. Standard ophthalmologist exams without OCT and fundus autofluorescence may miss it.

If you receive a diagnosis of pigmentary maculopathy, consult counsel handling MDL 2973 cases. The confidential settlement track is active; counsel familiar with the current valuation patterns can give you a realistic picture of what to expect. Most firms in this space work on contingency, so the consultation is free.

If your cumulative exposure was light (less than a year or so at standard dose) and you have no symptoms, the medical risk is lower and there is no immediate action to take. Be aware that the latency for pigmentary maculopathy is long, and surveillance ophthalmology visits at five-year intervals are a reasonable precaution.

The settlements are ongoing. The procedural framework is unusually opaque for a mass tort of this size. The medical facts are clear: pigmentary maculopathy is a real, distinct, irreversible condition caused by Elmiron exposure, and the warning came two decades too late.